Uscom Ltd represents values of innovation, excellence, and integrity. With a strong corporate philosophy focused on delivering advanced medical devices, Uscom Ltd is committed to improving patient outcomes and revolutionizing diagnostic solutions. With a passion for research and development, the company aims to provide cutting-edge technology in the field of cardiovascular health. Uscom Ltd's dedication to quality and accuracy sets them apart, ensuring healthcare professionals have access to accurate diagnostic tools for optimal patient care. By embodying these values, Uscom Ltd continues to make significant contributions to the healthcare industry.

Uscom Ltd is primarily present in Australia and the Asia-Pacific region.

Uscom Ltd has achieved several significant milestones in its journey. The company has successfully developed and patented non-invasive cardiovascular monitoring technologies, such as the USCOM 1A device. Uscom's USCOM 1A has been internationally recognized and adopted by healthcare professionals for its accuracy in measuring hemodynamic parameters. Uscom Ltd has also expanded its presence globally, with distribution agreements established in various countries. Furthermore, the company has received regulatory approvals, such as the CE Mark and clearance from the US FDA, enabling it to provide its innovative solutions to a wider market. Uscom Ltd continues to pave the way for advancements in cardiovascular monitoring technology.

Uscom Ltd, headquartered in Sydney, Australia, is a medical device company specializing in non-invasive cardiovascular and pulmonary monitoring equipment. Established in 2000, the company has a rich history in developing innovative medical technologies. Uscom's flagship product, the Uscom 1A, is a non-invasive, portable device that provides real-time measurements of cardiac output, blood pressure, and other vital cardiovascular parameters. With a global presence, Uscom has achieved remarkable success in the medical industry by offering advanced medical solutions. Combining cutting-edge technology and clinical expertise, Uscom continues to lead the way in non-invasive monitoring for the advancement of patient care worldwide.

The main competitors of Uscom Ltd in the market include global medical device companies such as Edwards Lifesciences Corporation, Masimo Corporation, and Nonin Medical Inc. These companies also specialize in developing and manufacturing medical devices and technologies, particularly focused on cardiovascular care and continuous non-invasive monitoring. Uscom Ltd competes with these industry leaders by offering unique and innovative products, such as its non-invasive hemodynamic monitoring systems. As Uscom Ltd continues to expand its market presence and enhance its product offerings, it aims to effectively compete with these key players in the medical device market.

Uscom Ltd is primarily active in the medical device industry.

The business model of Uscom Ltd is centered around the development and commercialization of non-invasive medical devices for the assessment of cardiovascular and pulmonary function. Uscom specializes in the manufacturing of innovative devices that provide accurate and reliable measurements of various hemodynamic parameters. Their products, such as the Uscom 1A, are designed to assist healthcare professionals in diagnosing and managing cardiovascular conditions. By leveraging their expertise in medical technology and continuous innovation, Uscom aims to improve patient outcomes and enhance the efficiency of medical care in cardiology and other related fields.

Pašreizējais KGV Uscom nevar tikt aprēķināts.

KUV šobrīd Uscom nevar aprēķināt.

AlleAktien kvalitātes vērtējums Uscom ir 5/10.

Pašreiz nevar aprēķināt apgrozījumu Uscom.

Pašlaik peļņa Uscom nevar tikt aprēķināta.

Uscom Ltd is an Australian medical technology company specializing in non-invasive cardiovascular diagnostics. The company's business model is based on the development, manufacture, and sale of innovative medical devices and solutions that enable more precise and effective diagnosis and monitoring of heart diseases. Uscom is divided into two main divisions: clinical diagnostics and telemedical monitoring. In the clinical diagnostics division, Uscom offers the Doppler hemodynamic systems USCOM 1A and USCOM SpiroFlo for assessing hemodynamics in clinical settings. These devices are popular at leading medical institutions worldwide due to their high accuracy and user-friendliness. In the telemedical monitoring division, Uscom offers the USCOM BP+, a portable wireless blood pressure monitor that allows measurement and monitoring of blood pressure in non-clinical settings. With the USCOM BP+, doctors and nurses can monitor patients' blood pressure in real-time and ensure more accurate treatment. Uscom also produces a range of software solutions that enable seamless integration of USCOM devices into the medical infrastructure of hospitals and clinics. The USCOM CMS software (Cardiovascular Management System) is a web-based solution for managing patient data and generating reports. The USCOM SPIRO software enables integration of clinical spirometers into the USCOM system, providing a comprehensive solution for assessing patients' cardiorespiratory health. Uscom Ltd also grants licensing agreements to partner companies to distribute USCOM devices and solutions in specific regions or market segments. Currently, Uscom has licensing agreements in North America, Europe, Asia, and Australia. Uscom Ltd's business model is based on providing high-quality and innovative medical devices and solutions that enhance the accuracy and effectiveness of cardiovascular diagnosis and monitoring. The company works closely with leading medical professionals and institutions to ensure its products meet the highest standards. With a strong focus on research and development and a global presence, Uscom Ltd aims to be the preferred partner for medical professionals and institutions that require the most accurate and effective assessment of patients' cardiovascular health.

Uscom izmaksā dividendes 0 AUD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Uscom vai uzņēmums nedod dividendes.

Uscom ISIN ir AU000000UCM2.

Uscom WKN ir A0B7BV.

Uscom simbols ir UCM.AX.

Pēdējo 12 mēnešu laikā Uscom maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Uscom plāno maksāt dividendes 0 AUD apmērā.

Uscom pašreizējā dividendu rentabilitāte ir .

Uscom maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Uscom pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 AUD. Tas atbilst dividendes ražībai 0 %.

Uscom tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Uscom apmērā 0 AUD, kas tika izmaksāta 29.04.2025., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 29.04.2025..

Pēdējās dividendes izmaksa notika 29.04.2025..

Gadā 2024, Uscom izmaksāja 0 AUD dividendes.

Uscom dividendes tiek izmaksātas AUD.